When chronic subdural hematoma presents with mild or absent symptoms, the clinical decision is shaped significantly by the patient's overall surgical risk. For those with major comorbidities that make surgery high-risk, an evidence-based nonsurgical path exists.
This protocol applies to patients with chronic subdural hematoma who are mild-symptomatic or asymptomatic — a group in whom observation or nonsurgical management is frequently recommended, particularly when major comorbidities place them in a high surgical risk category.
The structured approach for this population focuses on nonsurgical management, incorporating a specific pharmacological strategy studied in a randomized controlled trial of patients with nonoperative chronic subdural hematoma. An adjunctive endovascular intervention targeting a meningeal vessel may also be considered alongside nonsurgical care.
The primary measurable goal is reduction of hematoma volume on CT imaging by 8 weeks, along with improved neurological outcome and avoidance of surgical bailout.
For patients with mild symptoms or for patients who are asymptomatic, observation is frequently recommended, particularly for patients with major comorbidities that place them in a high surgical risk category.
Jiang et al, in a randomized controlled trial (RCT) of atorvastatin therapy in 196 patients with nonoperative cSDH with mild symptoms, reported that after 8 weeks, patients in the atorvastatin group had a better hematoma volume reduction, a better neurological outcome, and a lower rate of surgical bailout.
Current data supports MMAE as an adjunct to conventional surgical or nonsurgical management.
View source ↗